They target the same outcome (tissue repair) through different mechanisms : BPC-157: local growth factor expression, fibroblast stimulation, angiogenesis at the injury site TB-500: systemic cell migration, actin regulation, reduction of chronic inflammation throughout the body Standard Wolverine stack: BPC-157: 250500 mcg SC twice daily , injected near the injury site where possible TB-500: 22.5 mg SC twice weekly loading (weeks 14), then 2 mg weekly maintenance (weeks 512) CRITICAL: do not mix in the same vial - they can be injected in the same session but must remain in separate solutions
NUEM Blog
Federman DG, Froelich CW, Kirshner RS
The phrase researchers keep coming back to is "modulate, not suppress." KPV tones down excess signaling rather than disabling the immune response, so the body's normal defenses are meant to stay intact
Haggerty KL, Campetti R, Stoeckle RJ, EpsteinLubow G, Evertson LC, Spragens L